Cargando…
Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference
Antiviral responses are barriers that must be overcome for efficacy of oncolytic virotherapy. In mammalian cells, antiviral responses involve the interferon pathway, a protein-signaling cascade that alerts the immune system and limits virus propagation. Tumour-specific defects in interferon signalin...
Autores principales: | Bastin, Donald, Aitken, Amelia S., Pelin, Adrian, Pikor, Larissa A., Crupi, Mathieu J. F., Huh, Michael S., Bourgeois-Daigneault, Marie-Claude, Bell, John C., Ilkow, Carolina S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008949/ https://www.ncbi.nlm.nih.gov/pubmed/29921327 http://dx.doi.org/10.1186/s40425-018-0366-2 |
Ejemplares similares
-
Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
por: Roy, D. G., et al.
Publicado: (2021) -
Pre-surgical oncolytic virotherapy improves breast cancer outcomes
por: Mullins-Dansereau, Victor, et al.
Publicado: (2019) -
ONCOLYTIC VIROTHERAPY
por: Russell, Stephen J, et al.
Publicado: (2012) -
Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022) -
Exploiting tumor epigenetics to improve oncolytic virotherapy
por: Forbes, Nicole E., et al.
Publicado: (2013)